JP MORGAN/CALL/MEDTRONIC/100/0.1/16.01.26 Share Price

Warrant

DE000JT3GYK7

Market Closed - Börse Stuttgart 08:29:47 04/07/2024 pm IST
0.28 EUR -6.67% Intraday chart for JP MORGAN/CALL/MEDTRONIC/100/0.1/16.01.26
Current month-15.15%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
04/24/04 0.28 -6.67%
03/24/03 0.3 +7.14%
02/24/02 0.28 -15.15%
01/24/01 0.33 0.00%
28/24/28 0.33 -5.71%

Delayed Quote Börse Stuttgart

Last update July 04, 2024 at 08:29 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JT3GYK
ISINDE000JT3GYK7
Date issued 12/06/2024
Strike 100 $
Maturity 16/01/2026 (561 Days)
Parity 10 : 1
Emission price 0.38
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.42
Lowest since issue 0.28
Spread 0.1
Spread %25.64%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.17 USD
Average target price
94.02 USD
Spread / Average Target
+21.84%
Consensus